CogenDx will present the study at the American Society for Clinical Pharmacology & Therapeutics Annual Meeting in Washington D.C., March 15-18
SAN DIEGO – March 16, 2017 – CogenDx, which offers genetic testing to identify how a patients’ genetic profile may impact his or her response to certain medications, unveils one of the largest studies of variation of the drug-metabolizing gene CYP2D6 in the US population. The study revealed that a wide range of different CYP2D6 genes, including the difficult-to-detect structural variants, are found in Americans. CYP2D6 metabolizes approximately one-quarter of prescribed medications, and the observed genetic diversity may explain why many patients do not respond well or have intolerable side effects when taking medications such as certain antidepressants, antipsychotics and opioids. The study was a collaboration with Children’s Mercy Kansas City.